Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

NO_LONGER_AVAILABLE

Conditions studied: Multiple Myeloma

In brief

This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.

Key facts

Study ID

NCT04453397

Run by

TeneoOne Inc.

Last updated by the study team

2021-09-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adequate bone marrow function
• eGFR ≥ 30 mL/min
• Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
• Serum calcium (corrected for albumin) at or below the ULN range

You may not qualify if…

• Candidate for treatment regimens known to provide clinical benefit in MM
• Active infection requiring parenteral anti-infective treatment
• Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety

Where it is running

• Wake Forest — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.